Reply to R.L. Nussbaum et al and J.S. Dolinsky et al

Judith Balmaña¹, Katherine Nathanson¹, Kenneth Offit¹+2

• ¹Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.